期刊
CANCER
卷 127, 期 14, 页码 2489-2499出版社
WILEY
DOI: 10.1002/cncr.33508
关键词
acute myeloid leukemia; azole antifungals; invasive fungal infection; prophylaxis; venetoclax
类别
资金
- National Institutes of Health [R01 CA235622, P30 CA016672]
- Lloyd Family Scholar Award from the V Foundation
Background: Venetoclax combined with HMA improves survival in elderly patients with AML. However, this treatment can lead to profound neutropenia, requiring antifungal prophylaxis. Limited data exist on the outcomes of patients receiving VEN, HMA, and azoles.
Background Venetoclax (VEN) combined with the hypomethylating agent (HMA) azacitidine improves survival in patients aged >= 75 years with newly diagnosed acute myeloid leukemia (AML). VEN and HMA treatment can result in prolonged and often profound neutropenia, and this warrants antifungal prophylaxis. Azole antifungals inhibit cytochrome P450 3A4, the primary enzyme responsible for VEN metabolism; this results in VEN dose reductions for each concomitant antifungal. Limited clinical data exist on outcomes for patients treated with VEN, an HMA, and various azoles. Methods The time to neutrophil recovery (absolute neutrophil count [ANC] > 1000 cells/mm(3)) and platelet (PLT) recovery (PLT count > 100,000 cells/mm(3)) in 64 patients with newly diagnosed AML who achieved a response after course 1 of VEN plus an HMA were evaluated. HMA therapy included azacitidine (75 mg/m(2) intravenously/subcutaneously for 7 days) or decitabine (20 mg/m(2) intravenously for 5 or 10 days). Results Forty-seven patients (73%) received an azole: posaconazole (n = 17; 27%), voriconazole (n = 9; 14%), isavuconazole (n = 20; 31%), or fluconazole (n = 1; 2%). The median time to ANC recovery were similar for patients who did receive an azole (37 days; 95% confidence interval [CI], 34-38 days) and patients who did not receive an azole (39 days; 95% CI, 30 days to not estimable; P = .8). The median time to PLT recovery was significantly longer for patients receiving azoles (28 vs 22 days; P = .01). The median times to ANC recovery (35 vs 38 days) and PLT recovery (26 vs 32 days) were similar with posaconazole and voriconazole. Conclusions VEN plus an HMA resulted in neutropenia and thrombocytopenia, with the latter prolonged in patients receiving concomitant azoles. Concomitant posaconazole or voriconazole and VEN (100 mg) resulted in similar ANC and PLT recovery times, suggesting the safety of these dosage combinations during course 1.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据